Safety of ustekinumab and vedolizumab during pregnancy—pregnancy, neonatal, and infant outcome: A prospective multicentre study

K Mitrova, B Pipek, M Bortlik, L Bouchner… - Journal of Crohn's …, 2022 - academic.oup.com
Abstract Background and Aims Evidence on the safety of newer biologics during pregnancy
is limited. We aimed to assess the safety of ustekinumab and vedolizumab treatment during …
被引用次数：27 相关文章

Safety of Ustekinumab and Vedolizumab During Pregnancy—Pregnancy, Neonatal, and Infant Outcome: A Prospective Multicentre Study

K Mitrova, B Pipek, M Bortlik, L Bouchner… - Journal of Crohn's …, 2022 - academic.oup.com
Abstract Background and Aims Evidence on the safety of newer biologics during pregnancy
is limited. We aimed to assess the safety of ustekinumab and vedolizumab treatment during …

Safety of Ustekinumab and Vedolizumab During Pregnancy-Pregnancy, Neonatal, and Infant Outcome: A Prospective Multicentre Study

K Mitrova, B Pipek, M Bortlik… - Journal of Crohn's …, 2022 - pubmed.ncbi.nlm.nih.gov
Background and aims Evidence on the safety of newer biologics during pregnancy is limited.
We aimed to assess the safety of ustekinumab and vedolizumab treatment during gestation …

Safety of ustekinumab and vedolizumab during pregnancy-pregnancy, neonatal and infant outcome: a prospective multicenter study.

K Mitrova, B Pipek, M Bortlik, L Bouchner… - Journal of Crohn's & …, 2022 - europepmc.org
Methods We performed a prospective multicenter observational study in consecutive women
with inflammatory bowel disease exposed to ustekinumab or vedolizumab 2 months prior to …

Safety of Ustekinumab and Vedolizumab During Pregnancy—Pregnancy, Neonatal, and Infant Outcome: A Prospective Multicentre Study.

K Mitrova, B Pipek, M Bortlik… - Journal of Crohn's …, 2022 - search.ebscohost.com
Abstract Background and Aims Evidence on the safety of newer biologics during pregnancy
is limited. We aimed to assess the safety of ustekinumab and vedolizumab treatment during …